Association Between De Novo C1q-Binding Donor-Specific Anti-HLA Antibodies and Clinical Outcomes After Kidney Transplantation: A Meta-Analysis
Transplantation Proceedings · 2024-11 · 56 (9) · 1976-1983
DOI: 10.1016/j.transproceed.2022.10.054 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Transplantation Proceedings, 2024-11. Verfasst von Nur Rasyid und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia. Hauptthemen laut MEDLINE: Kidney Transplantation, Complement C1q, Graft Rejection, HLA Antigens. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Donor-specific antibodies (DSAs) are recognized as an important factor of kidney allograft loss as a subsequent event of antibody-mediated rejection (AMR). The clinical relevance of de novo DSAs (dnDSAs) after kidney transplant, particularly in their ability to bind C1q, has been widely investigated to various extents among studies. A recent study was performed to examine the association between C1q-binding dnDSAs and succeeding clinical events after kidney transplant. METHODS: A meta-analysis of studies published before April 2021 was conducted from PubMed, Science Direct, and Cochrane databases. Publications on dnDSA after kidney transplant focusing on differentiation between C1q-binding and non-C1q-binding were included. The outcomes analyzed were AMR rate and allograft loss. Studies using preformed DSA were excluded. The pooled risk ratio and 95% confidence interval (CI) were analyzed using Mantzel-Haenzel method, and the I2 value was used to determine the heterogeneity of the studies. Data analysis was conducted using Review Manager 5.3. RESULTS: A total of 535 patients from 13 studies who developed dnDSA after kidney transplant were analyzed. Among these, 239 (44.7%) had C1q-binding and 296 (55.3%) had non-C1q-binding dnDSA. Acute AMR was found in 59.2% (97/164) of the C1q-binding group and in 28.8% (49/170) of the non-C1q-binding group (risk ratio [RR], 0.58 [95% CI, 0.39-0.85], P = .006, I2 = 58%). Chronic AMR was found in 50% (19/38) of the C1q-binding group and in 16.9% (11/65) of the non-C1q-binding group (RR, 0.39 [95% CI, 0.21-0.71], P = .002, I2 = 0%). Allograft loss was found in 62.2% (74/119) of the C1q-binding group and in 34.1% (60/176) of the non-C1q-binding group (RR, 0.57 [95% CI, 0.38-0.85], P = .006, I2 = 61%). CONCLUSIONS: This meta-analysis demonstrates that patients who developed C1q-binding dnDSA display an increased risk of AMR and allograft loss compared with those with non-C1q-binding dnDSA. Therefore, C1q-binding dnDSAs are associated with inferior outcomes after kidney transplant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
- Department of Urology, Faculty of Medicine, Universitas Udayana, Bali, Indonesia. Electronic address: gwkurology@gmail.com.
- Department of Urology, Faculty of Medicine, Universitas Udayana, Bali, Indonesia.
Zitieren
APA
Rasyid, N., Duarsa, G. W. K., Tirtayasa, P. M. W., Situmorang, G. R., & Rodjani, A. (2024). Association Between De Novo C1q-Binding Donor-Specific Anti-HLA Antibodies and Clinical Outcomes After Kidney Transplantation: A Meta-Analysis. Transplantation Proceedings, 56(9), 1976-1983. https://doi.org/10.1016/j.transproceed.2022.10.054
Vancouver
Rasyid N, Duarsa GWK, Tirtayasa PMW, Situmorang GR, Rodjani A. Association Between De Novo C1q-Binding Donor-Specific Anti-HLA Antibodies and Clinical Outcomes After Kidney Transplantation: A Meta-Analysis. Transplantation Proceedings. 2024;56(9):1976-1983. doi:10.1016/j.transproceed.2022.10.054
BibTeX
@article{Rasyid2024,
author = {Rasyid, Nur and Duarsa, Gede Wirya Kusuma and Tirtayasa, Pande Made Wisnu and Situmorang, Gerhard Reinaldi and Rodjani, Arry},
title = {Association Between De Novo C1q-Binding Donor-Specific Anti-HLA Antibodies and Clinical Outcomes After Kidney Transplantation: A Meta-Analysis},
journal = {Transplantation Proceedings},
year = {2024},
volume = {56},
number = {9},
pages = {1976--1983},
doi = {10.1016/j.transproceed.2022.10.054}
}
EUVIMED